Federal contract award
75N93020C00037
TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AJ12 — GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $9.0M |
| Current contract value | $9.0M |
| Potential contract value / ceiling | $9.3M |
| Start date | Sep 1, 2020 |
| Current end date | May 31, 2026 |
| Potential end date | May 31, 2026 |
| Latest award activity | Aug 20, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 16 of 16 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 20, 2026 | P00015 | $-964.8K | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Mar 11, 2026 | P00014 | $0 | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Apr 16, 2025 | P00013 | $0 | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Jan 10, 2025 | P00012 | $-146.1K | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Nov 19, 2024 | P00011 | $1.0M | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Jul 10, 2024 | P00010 | $0 | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Mar 19, 2024 | P00009 | $0 | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Jul 3, 2023 | P00008 | $1.1M | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Mar 10, 2023 | P00007 | $0 | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Feb 22, 2023 | P00006 | $0 | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Dec 7, 2022 | P00005 | $0 | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| May 31, 2022 | P00004 | $0 | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Dec 29, 2021 | P00003 | $194.5K | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Sep 24, 2021 | P00002 | $0 | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Jun 21, 2021 | P00001 | $5.0M | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
| Aug 20, 2020 | 0 | $2.8M | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Apr 8, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Apr 8, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Apr 1, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Apr 1, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Mar 26, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Mar 26, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Mar 20, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Mar 20, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Mar 13, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Mar 13, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Mar 6, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Mar 6, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Feb 27, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Feb 27, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Feb 24, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Feb 24, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Feb 13, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Feb 13, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Feb 4, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Feb 4, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Jan 21, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Jan 21, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Jan 3, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Jan 3, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Jan 3, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Jan 3, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Dec 11, 2019 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Dec 11, 2019 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.